| P50 | author | Mark J Ratain | Q87725760 |
| P2093 | author name string | Linda Janisch | |
| | Peter H. O'Donnell | |
| | Walter M. Stadler | |
| | M. Kelly Nicholas | |
| | Samir D. Undevia | |
| | Theodore M. Karrison | |
| P2860 | cites work | Biochimica et Biophysica Acta | Q864239 |
| | Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling | Q46158906 |
| | Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma | Q46837791 |
| | Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides | Q47881843 |
| | Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design | Q57714784 |
| | Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts | Q28216709 |
| | Signalling via integrins: implications for cell survival and anticancer strategies | Q28272370 |
| | Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels | Q29619679 |
| | N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists | Q30580638 |
| | A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer | Q33265964 |
| | Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. | Q33375093 |
| | Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. | Q34756781 |
| | Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme | Q34871632 |
| | Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours | Q40592751 |
| | Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist | Q43517798 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 604-610 | |
| P577 | publication date | 2010-09-14 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | A phase I study of continuous infusion cilengitide in patients with solid tumors | |
| P478 | volume | 30 | |